2022
Prognosis of hospitalized patients with cirrhosis and acute kidney disease
Wong F, Garcia‐Tsao G, Reddy KR, O'Leary JG, Kamath PS, Tandon P, Lai JC, Vargas HE, Biggins SW, Fallon MB, Thuluvath PJ, Maliakkal BJ, Subramanian R, Thacker L, Bajaj JS. Prognosis of hospitalized patients with cirrhosis and acute kidney disease. Liver International 2022, 42: 896-904. PMID: 35023264, PMCID: PMC11075740, DOI: 10.1111/liv.15154.Peer-Reviewed Original ResearchConceptsAcute kidney diseaseStage 1 AKIAKD patientsPeak ScrAKI patientsCirrhotic patientsKidney diseaseSecond infectionEnd-stage liver diseaseDecompensated cirrhotic patientsHigher hospital admissionsWorse renal dysfunctionNormal renal functionGlomerular filtration rateNorth American ConsortiumBaseline SCrRenal dysfunctionPrompt treatmentRenal functionSerum creatinineHospital admissionClinical outcomesLiver diseasePredictive factorsFiltration rate
2012
Association of AKI With mortality and complications in hospitalized patients with cirrhosis
Belcher JM, Garcia‐Tsao G, Sanyal AJ, Bhogal H, Lim JK, Ansari N, Coca SG, Parikh CR, Consortium F. Association of AKI With mortality and complications in hospitalized patients with cirrhosis. Hepatology 2012, 57: 753-762. PMID: 22454364, PMCID: PMC3390443, DOI: 10.1002/hep.25735.Peer-Reviewed Original ResearchConceptsAcute kidney injuryAcute Kidney Injury Network definitionAssociation of AKIDefinition of AKISeverity of AKIProgression of AKIProspective observational cohort studyAKIN stage 1Baseline renal functionObservational cohort studyIncidence of mortalityAKI criteriaAKI severityAKI stageAKIN criteriaAKIN stageHospital mortalityKidney injuryCohort studyDevastating complicationRenal functionHospitalized patientsImproved outcomesEarly diagnosisTimely treatment
2011
Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1*
Boyer TD, Sanyal AJ, Garcia‐Tsao G, Regenstein F, Rossaro L, Appenrodt B, Gülberg V, Sigal S, Bexon AS, Teuber P, Group T. Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1*. Liver Transplantation 2011, 17: 1328-1332. PMID: 21837734, PMCID: PMC3760727, DOI: 10.1002/lt.22395.Peer-Reviewed Original ResearchConceptsHepatorenal syndrome type 1Liver transplantationHepatorenal syndromeSyndrome type 1Nontransplant patientsTransplant patientsSurvival benefitSurvival rateType 1Pretransplant renal functionUse of terlipressinClear survival benefitCohort of patientsSurvival of patientsHRS reversalPosttransplant managementLiver transplantPosttransplant survivalMost patientsPosttransplant outcomesRenal functionPoor prognosisTerlipressinPatientsTransplantation
2010
Renal Dysfunction Is the Most Important Independent Predictor of Mortality in Cirrhotic Patients With Spontaneous Bacterial Peritonitis
Tandon P, Garcia–Tsao G. Renal Dysfunction Is the Most Important Independent Predictor of Mortality in Cirrhotic Patients With Spontaneous Bacterial Peritonitis. Clinical Gastroenterology And Hepatology 2010, 9: 260-265. PMID: 21145427, PMCID: PMC3713475, DOI: 10.1016/j.cgh.2010.11.038.Peer-Reviewed Original ResearchConceptsRenal dysfunctionCirrhotic patientsBacterial peritonitisAscitic fluid cell countHigh-risk patientsMain prognostic factorsNormal renal functionSpontaneous bacterial peritonitisHigh-risk groupImportant independent predictorBlood urea nitrogenGood quality studiesSBP resolutionVasoconstrictor therapyMELD scoreAdult patientsRenal functionIndependent predictorsMedian agePrognostic factorsRisk stratificationCommon infectionsImmunosuppressive factorsPrognostic valuePrognostic studies
2008
A Randomized, Prospective, Double-Blind, Placebo-Controlled Trial of Terlipressin for Type 1 Hepatorenal Syndrome
Sanyal AJ, Boyer T, Garcia–Tsao G, Regenstein F, Rossaro L, Appenrodt B, Blei A, Gülberg V, Sigal S, Teuber P, Group T. A Randomized, Prospective, Double-Blind, Placebo-Controlled Trial of Terlipressin for Type 1 Hepatorenal Syndrome. Gastroenterology 2008, 134: 1360-1368. PMID: 18471513, PMCID: PMC3730280, DOI: 10.1053/j.gastro.2008.02.014.Peer-Reviewed Original ResearchMeSH KeywordsDose-Response Relationship, DrugDouble-Blind MethodFemaleFollow-Up StudiesGermanyHepatorenal SyndromeHumansInjections, IntravenousKidney Function TestsLypressinMaleMiddle AgedProspective StudiesRussiaSeverity of Illness IndexShock, SepticSurvival RateTerlipressinTreatment OutcomeUnited StatesVasoconstrictor AgentsConceptsHRS type 1Type 1 HRSSCr levelsTreatment successDay 14Type 1Total adverse event rateType 1 hepatorenal syndromePlacebo-controlled clinical trialSafety of terlipressinTrial of terlipressinAdvanced liver diseaseFunctional renal failureNonfatal myocardial infarctionSerum creatinine levelsTransplantation-free survivalAdverse event ratesSyndrome type 1Arterial vasoconstrictorHepatorenal syndromeHRS reversalCreatinine levelsRenal failureRenal functionLiver disease
2003
The management of ascites in cirrhosis: Report on the consensus conference of the international Ascites club
Moore K, Wong F, Gines P, Bernardi M, Ochs A, Salerno F, Angeli P, Porayko M, Moreau R, Garcia‐Tsao G, Jimenez W, Planas R, Arroyo V. The management of ascites in cirrhosis: Report on the consensus conference of the international Ascites club. Hepatology 2003, 38: 258-266. PMID: 12830009, DOI: 10.1053/jhep.2003.50315.Peer-Reviewed Original ResearchConceptsTransjugular intrahepatic portosystemic stent shuntInternational Ascites ClubDiuretic therapyRefractory ascitesColloid volume expansionModest salt restrictionLarge-volume paracentesisManagement of ascitesDevelopment of ascitesHepatic decompensationModerate ascitesGross ascitesLiver transplantationRenal dysfunctionSalt restrictionSodium excretionSodium restrictionTherapeutic paracentesisRenal functionSurvival benefitCommon complicationLiver diseasePancreatic ascitesAscitic patientsTIPS placement